ArticleAnnals of the rheumatic diseases2000
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
Article in Annals of the rheumatic diseases, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 292 citations in OpenAlex.
- Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action.Clinical rheumatology · 2021Pooled it
- A psychometric analysis of outcome measures in peripheral spondyloarthritis.Annals of the rheumatic diseases · 2016Trial
- Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.Annals of the rheumatic diseases · 2005Trial
- The effect of infliximab on extraintestinal manifestations of Crohn's disease.Rheumatology international · 2005Trial
- Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.Annals of the rheumatic diseases · 2005Trial
- Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy.Annals of the rheumatic diseases · 2005Trial
- Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations.Annals of the rheumatic diseases · 2004Trial
- Cytokine blockers in psoriatic arthritis.Annals of the rheumatic diseases · 2001Trial
- Efficacy and safety of IL inhibitors, TNF-α inhibitors, and JAK inhibitors in patients with ankylosing spondylitis: a systematic review and Bayesian network meta-analysis.Annals of translational medicine · 2023Article
- Predicting Hepatotoxicity Associated with Low-Dose Methotrexate Using Machine Learning.Journal of clinical medicine · 2023Article
- Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis.Nature reviews. Rheumatology · 2020Review
- Observational
- High-dose thalidomide increases the risk of peripheral neuropathy in the treatment of ankylosing spondylitis.Neural regeneration research · 2015Article
- The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.Arthritis research & therapy · 2013Observational
- Psychometric characteristics of the short form 36 health survey and functional assessment of chronic illness Therapy-Fatigue subscale for patients with ankylosing spondylitis.Health and quality of life outcomes · 2011Article
- Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis.The open rheumatology journal · 2011Article
- Undifferentiated spondyloarthritis: recent clinical and therapeutic advances.Current rheumatology reports · 2010Review
- A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis.Rheumatology international · 2009Review
- Management of ankylosing spondylitis with infliximab.Open access rheumatology : research and reviews · 2009Review
- [Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis].Wiener medizinische Wochenschrift (1946) · 2008Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of a loading dose regimen of three intravenous infusions with infliximab in patients with active spondyloarthropathy.
methodsA monocentre, open-label pilot study of 21 patients with different subtypes of spondyloarthropathy was conducted. Treatment resistant patients with active disease (fulfilling inclusion criteria) received three infusions of 5 mg/kg infliximab (at weeks 0, 2, and 6). Standard clinical assessments were performed at baseline, and on days 3, 7, and 14, and from then on every two weeks. In patients who fulfilled criteria for ankylosing spondylitis, axial assessment was performed at baseline and on days 14, 42, and 84.
resultsIn all global assessments (visual analogue scale of patient global assessment, patient pain assessment, doctor global assessment), erythrocyte sedimentation rate, and C reactive protein, a highly significant decrease could be seen already at day 3 (compared with baseline), which was maintained up to day 84. In patients with peripheral disease (n=18), tender and swollen joint count significantly decreased. In patients with axial disease (n=11), functional and disease activity indices significantly improved. Moreover in eight patients with psoriatic arthritis a significant decrease of the psoriasis area and severity index was observed. The treatment was well tolerated in all patients; no significant adverse events were seen.
conclusionIn this open-label pilot study of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha in patients with active spondyloarthropathy, there was a fast and significant improvement of axial and peripheral articular manifestations, without major adverse experiences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.